SAN FRANCISCO, March 21, 2023 (GLOBE NEWSWIRE) — Hagens Berman calls on LivePerson, Inc. LPSN Investors who have suffered significant losses Submit your losses now.

Visit: www.hbsslaw.com/investor-fraud/LPSN
Contact a lawyer now: LPSN@hbsslaw.com
844-916-0895

LivePerson, Inc. (LPSN) Investigation:

The investigation focuses on LivePerson’s disclosures regarding its WildHealth business, which the company acquired in February 2022.

Notably, LivePerson recently assured investors that it “expects[ed] strong performance by WildHealth […] in the fourth quarter” and has provided repeated assurances to investors that its financial controls and procedures are effective.

LivePerson’s statements were first challenged on February 28, 2023, when the company announced that it would not file its annual financial report on time. The company stated that it “needs more time to complete additional reviews and revenue recognition testing related to a recently terminated WildHealth program for which Medicare reimbursement is suspended[.]”

Then, on March 15, 2023, LivePerson reported dismal fourth-quarter 2022 financial results and a weak 2023 outlook of the Medicare demonstration program. LivePerson also announced that it recognized a reserve for revenue related to WildHealth services rendered under the program in the fourth quarter of 2022.

On March 16, 2023, LivePerson filed its annual financial report, revealing material weaknesses in its internal control over financial reporting related to its WildHealth subsidiary transactions.

These events caused LivePerson’s stock price to fall sharply.

“We are focused on investor losses and whether LivePerson may have misled investors as to whether WildHealth provided reimbursable services under the Medicare program,” said Reed Kathrein, Hagens Berman…